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Achieving symptom control in patients with Moderate Asthma
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and Lung Inflammation, Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National 
Institutes of Health, Bethesda, MD. Corresponding author email: levines@nhlbi.nih.gov
Abstract: Disease severity in asthma can be classified as mild, moderate or severe based upon the frequency of symptoms or the 
severity of airflow obstruction. This review will focus on the treatment of youths greater than 12 years of age and adults with moderate 
persistent asthma. Moderate asthmatics may have daily symptoms that cause some limitation with normal daily activities and require 
use of a rescue inhaled short-acting beta
2
-agonist inhaler or experience nocturnal awakenings secondary to asthma that occur more 
than once per week. Furthermore, spirometry may reveal airflow obstruction with a reduction in FEV
1
 to between 60% and 80% of 
predicted. Although inhaled corticosteroids (ICS) are the primary controller medication used to modify symptoms in moderate asthmat-
ics, additional controller medications, such as inhaled long-acting beta
2
-agonists (LABA), leukotriene receptor antagonists (LTRA) or 
theophylline, are often needed to obtain optimal disease control. While the addition of an inhaled LABA to an ICS is very effective at 
improving disease control in moderate asthma, concerns have arisen over the safety of LABAs, in particular the risk of asthma-related 
death. Therefore, consideration may be given to initially adding a LTRA, rather than a LABA, to ICS when asthma symptoms are not 
adequately controlled by ICS alone. Furthermore, individualization of medication regimens, treatment of co-morbid conditions, and 
patient education are crucial to optimizing compliance with therapy, improving disease control, and reducing the risk of exacerbations. 
Lastly, the development of new asthma treatments, perhaps based upon personalized medicine, may revolutionize the future treatment 
of moderate asthma.
Keywords: asthma, inhaled corticosteroids, long-acting beta2-agonists, leukotriene modifiers, leukotriene receptor antagonists, theophylline
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Asthma is a chronic inflammatory disease of the 
 airway that is highly prevalent in both children and 
adults. The World Health Organization estimates that 
approximately 245 million individuals suffer from 
asthma worldwide, while the Centers for  Disease 
Control reported that asthma prevalence in the 
United States was 8.2% in 2009, which represents 
approximately 24.6 million individuals.1,2 The Expert 
Panel 3 Report (EPR-3) from the National Asthma 
Education and Prevention Program (NAEPP) of 
the National Heart, Lung, and Blood Institute 
(NHLBI) defines asthma as the presence of “variable 
and recurring symptoms, airflow obstruction, 
bronchial hyperresponsiveness, and an underlying 
inflammation,” which are commonly triggered by 
exposure to allergens, irritants or cold air, as well as by 
viral infections or exercise.3 The clinical manifestations 
of asthma are typified by intermittent symptoms of 
cough, wheeze, chest tightness or dyspnea, that often 
occur in individuals with a personal or family history 
of allergy and/or other common diseases, such as 
gastroesophageal reflux or chronic rhinosinusitis. 
Asthma symptoms and physiologic evidence of 
airflow obstruction are caused by underlying airway 
inflammation (cellular infiltration by activated T helper 
lymphocytes, eosinophils, neutrophils and mast cells 
with associated edema), airway remodeling (increased 
airway secretions, airway epithelial cell and smooth 
muscle hyperplasia, epithelial cell desquamation, 
goblet cell hyperplasia and collagen deposition), and 
smooth muscle constriction.4
Characterization of a patient’s asthma severity is 
a critical guide for the initiation of asthma treatment 
and the determination of future risk of deterioration. 
Disease severity can be classified as mild, moderate or 
severe based upon the frequency of asthma symptoms 
or the severity of airflow obstruction (Fig. 1).3 While 
the majority of asthmatics have mild disease, those with 
moderate or severe asthma have more frequent symp-
toms that are difficult to control.5,6 This review will 
focus on the treatment of youths greater than 12 years 
of age and adult patients with moderate persistent 
asthma. Moderate asthmatics have daily symptoms or 
nocturnal awakenings secondary to asthma that occur 
more than once per week, but not nightly. On spirom-
etry, moderate asthmatics have an FEV
1
 between 60% 
and 80% of predicted, and their FEV
1
/FVC ratios are 
generally reduced by 5% or less when compared with 
predicted values. In addition, they may require daily 
use of an inhaled short-acting beta
2
-agonist (SABA) 
for control of their asthma symptoms and also experi-
ence some limitation with normal daily activities.
The EPR-3 recommends a step care approach that 
matches the intensity of treatment to disease sever-
ity and adequacy of control of asthma symptoms. 
As shown in Figures 1 and 2, the EPR-3 proposes 
Intermittent
Step 1 Step 2 Step 3 Step 4 or 5
FEV1/FVC reduced
>5%
FEV1 < 60%FEV1 > 60% but
<80% predicted
FEV1/FVC reduced
5%
FEV1/FVC normal FEV1/FVC normal 
FEV1 > 80%
predicted 
FEV1 > 80%
predicted 
Minor limitation 
>2 days/week
but not daily and
not more than 1x
on any day 
Extremely limited
Several times
per day
Often 7x/week
Through out
the day
Daily
Daily
3−4x/month
>2 days/week
but not daily
≤2 days/week
≤2 days/week
≤2x/month
None Some limitation
>1x/week, but
not nightly
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Severe
Symptoms
Night time
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Interference with
normal activity
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Recommend step for
Initiating treatment
short-acting
beta2-agoinst use for
symptom control
Figure 1. NHLBI National Asthma and Education and Prevention Program Expert Panel 3 Report classification of asthma severity in youths $ 12 years 
of age and adults.
Adapted from National Asthma education and Prevention Program. expert Panel Report 3: Guidelines for the diagnosis and management of asthma. 
National Heart, Lung, and Blood Institute, National Institutes of Health, US. Department of Health and Human Services. 2007.
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that moderate asthmatics initiate treatment at Step 3 
or 4.3 The objective of treatment is to decrease dis-
ease severity and improve control while providing 
optimally dosed medications with the fewest pos-
sible side effects. Furthermore, treatment is directed 
at decreasing the risk of future exacerbations, as well 
as reducing the loss of lung function over time. The 
specific benchmarks for improvement of symptoms 
are defined as a decrease in the use of short-acting 
beta
2
-agonists (SABA), a reduction in daytime and 
nocturnal asthma symptoms, an improvement in abil-
ity to conduct normal activities, and personal satis-
faction with the level of asthma control (Fig. 3). By 
periodically monitoring disease severity through 
patient visits and spirometry, the health care provider 
can determine the level of control and risk of future 
exacerbations within each patient and adjust therapy 
accordingly.
controller Medications for Moderate 
persistent Asthma
The mainstay of therapy for moderate asthma is the 
chronic administration of controller medications 
that modify disease severity by reducing airway 
inflammation and bronchoconstriction in patients 
with persistent disease. The EPR-3 recommends that 
inhaled corticosteroids (ICS) be utilized as the main 
controller medication to which adjunctive controller 
medications can be added. These include inhaled 
long-acting beta
2
-agonists (LABAs), leukotriene 
modifiers, or theophylline.3 The addition of allergen 
immunotherapy can also be considered for patients 
who have allergic asthma. In addition, patients are 
provided with short-acting beta-agonists (SABA) 
to be used as needed to provide bronchodilation for 
symptomatic relief.
Inhaled corticosteroids
The mainstay of treatment for moderate persistent 
asthma among youths over the age of twelve and adults 
are inhaled corticosteroids (ICS).3 Corticosteroids, via 
interactions with glucocorticoid receptors, are highly 
effective for the treatment of asthma based upon their 
broad anti-inflammatory effects, which are mediated 
via the suppressed transcription of pro-inflammatory 
genes, termed trans-repression, as well as the acti-
vation of many anti-inflammatory genes, termed 
 trans-activation.7 The clinical benefits of ICS therapy 
in asthma include improvements in disease severity, 
asthma control, quality of life, pulmonary function, 
airway hyperresponsiveness, disease  exacerbations, 
Step 1
Preferred:
SABA prn
Low-dose ICS Medium-dose ICS
Cromolyn,
LTRA,
Nedocromil or
Theophylline
Steps 2–4: Consider subcutaneous allergen
immunotherapy for patients who have allergic asthma
Steps 1–6:
Inhaled short-acting beta2-agonists (SABA) as needed for symptoms.
Patient education, enviromental control, and management of comorbidities.
Step up treatment if symptoms are not adequately controlled.
Step down treatment if asthma is well-controlled for 3 months to reduce side–effects and cost. 
Low-dose ICS +
either LTRA,
Theophylline, or
Zileuton
Medium-dose ICS
+ either LTRA,
Theophylline,or
Zileuton
Consider
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for patients who
have allergies
Consider
Omalizumab
for patients who
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AND
High-dose
ICS + LABA + oral
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Medium-dose
ICS + LABA
Low-dose
ICS + LABA
High-dose
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AND
Preferred:
Alternative:
Alternative:
Alternative:
Preferred:
preferred:
Preferred:
Preferred:
Step 2
Step 3
Step 4 
Step 5 
Step 6 
or
•
•
•
•
Figure 2. Stepwise approach for managing asthma in youths $ 12 years 
of age and adults as recommended by the NHLBI National Asthma and 
education and Prevention Program expert Panel 3 Report.
Adapted from National Asthma education and Prevention Program. 
expert Panel Report 3: Guidelines for the diagnosis and management of 
asthma. National Heart, Lung, and Blood Institute, National Institutes of 
Health, US. Department of Health and Human Services. 2007.
Impairment:
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Not
Well-Controlled
Very Poorly
Controlled
Throughout the day
≥ 4x/week
Extremely limited
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FEV1or peak flow
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•
•
•
•
•
•
•
•
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None
Figure 3. Assessing asthma control and adjustment of therapy in 
youths $ 12 years of age and adults as recommended by the NHLBI 
National Asthma and education and Prevention Program expert Panel 
3 Report.
notes: *ACQ values of 0.76 to 1.4 are indeterminate regarding well-
controlled asthma.
Adapted from National Asthma education and Prevention Program. 
expert Panel Report 3: Guidelines for the diagnosis and management of 
asthma. National Heart, Lung, and Blood Institute, National Institutes of 
Health, US. Department of Health and Human Services. 2007.
Abbreviations: ACQ, Asthma Control Questionnaire©; ACT, Asthma 
Control Test™; ATAQ, Asthma Therapy Assessment Questionnaire©.
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hospitalizations and death.3  Furthermore, ICS reduce 
the number of airway inflammatory cells (eosinophils, 
mast cells and T cells), as well as mucus production and 
hypersecretion, airway edema, and vascularization.4,8 
Therefore, all patients with moderate asthma should 
receive treatment with ICS.
A variety of ICS, either alone (Table 1) or in 
combination inhalers with LABAs (Table 2), are 
available for use in the United States. The potency 
of individual preparations differ based upon gluco-
corticoid receptor binding affinity, particle size, and 
the inhaler device used to deliver the medication.9 
Therefore, it is important for clinicians to ensure that 
therapeutic doses are prescribed. The advantage of 
ICS over oral corticosteroid therapy is a reduction in 
systemic side-effects due to site-directed delivery of 
the medication directly to the lung. However, only 
10% to 20% of the inhaled medication is delivered 
to the airway.10,11 The remainder is deposited in 
the oropharynx or swallowed and absorbed by the 
gastrointestinal tract, where most of the corticosteroid 
is converted to an inactive metabolite by “first pass 
metabolism” in the liver. Local side effects that may 
result from deposition of the ICS in the oropharynx and 
larynx include oropharyangeal candidiasis (thrush), 
dysphonia, cough, and throat irritation.10 Perioral 
dermatitis and tongue hypertrophy have also been 
reported.12 Local side-effects may be decreased by use 
of a spacer device, when possible, and by rinsing the 
mouth after use. Dose-dependent systemic toxicities 
of ICS occur when corticosteroids are absorbed from 
the lung or from the fraction that is not metabolized in 
the liver.8 The long-term systemic side effects that may 
impact adults when high doses of  ICS are administered 
include osteoporosis, cataract formation and adrenal 
suppression and crisis.8 In the elderly, skin changes and 
easy bruising may also be seen.10,13 In children, high 
doses of inhaled corticosteroids can be associated with 
a dose-related, short-term decrease in growth velocity, 
which does not appear to result in a substantial decrease 
in adult height, thereby suggesting the presence of 
compensatory mechanisms.10 Systemic toxicities, 
however, are less likely with medium-dose ICS that 
are typically utilized for the treatment of moderate 
persistent asthma. Furthermore, medium-dose ICS 
may improve disease control and thereby decrease the 
need for oral corticosteroids bursts, which are more 
likely to result in corticosteroid-induced osteopenia.8 Ta
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Long-acting beta2-agonists
β
2
-agonists induce bronchodilation via interacting 
with β
2
 adrenergic receptors to increase cAMP with 
resultant airway smooth muscle relaxation.3 β
2
-agonist 
medications can be classified by their duration 
of action. The effects of short-acting β
2
-agonists 
(SABAs), such as albuterol, persist for 4 to 6 hours, 
whereas the effects of long-acting β
2
-agonists 
(LABAs), such as salmeterol and formoterol, last for 
10 to 12 hours.14 Therefore, SABAs are recommended 
as a quick relief medication for asthma symptoms, 
whereas LABAs are considered a controller medica-
tion that attenuate bronchoconstriction, but do not 
modify underlying airway  inflammation. Consistent 
with this concept, the addition of an inhaled LABA 
to an ICS has been shown to improve lung func-
tion, decrease symptoms and reduce exacerbations 
in asthmatics who are not well controlled on low 
or medium doses of ICS.3 The EPR-3 recommends 
that patients with moderate persistent asthma may 
be treated with a combination of low-dose (Step 3) 
or medium dose (Step 4) ICS plus a LABA. Com-
bination inhalers facilitate delivery of the maximal 
recommended daily dose of LABA with varying 
doses of ICS (Table 2). The pharmacodynamics of 
inhaled salmeterol and formoterol differ. Inhaled 
salmeterol has an onset of action of between 30 and 
48  minutes with a peak effect at 3 hours.15 It has a 
half-life of 5.5 hours and undergoes hepatic metab-
olism by CYP3A4. In  contrast, inhaled formoterol 
has a rapid onset of action within 3 minutes of 
administration, with 80% of its peak effect evident 
within 15 minutes.16 The half-life of formoterol in 
powder form is approximately 10 to 14 hours, while 
nebulized formoterol has a half-life of approxi-
mately 7 hours. It undergoes hepatic metabolism 
via direct glucuronidation and O-demethylation by 
multiple cytochrome P450 enzymes. Arformoterol 
and indacaterol are new LABAs that have been 
approved by the US. Food and Drug Administration 
(FDA) for use in COPD, but not for the treatment of 
asthma.
Although the addition of an inhaled LABA to an 
ICS is very effective at improving disease control, 
concerns have arisen over the safety of LABAs. 
Prior to its approval by the FDA, the Serevent® 
Nationwide Surveillance Study noted an increase 
in risk of asthma-related death in patients treated 
with salmeterol as compared with albuterol.17 Based 
upon this study, as well as reports to the FDA of 
serious asthma exacerbations and deaths in patients 
treated with salmeterol, the manufacturer conducted 
the Salmeterol Multicenter Asthma Research Trial 
(SMART), which showed a small but significant 
increase in asthma-related deaths (1 in 700 patient-
years) in individuals receiving salmeterol without 
concurrent ICS over 28 weeks.18,19 The safety concern 
of increased risk of asthma-related deaths associated 
with the use of LABAs prompted the FDA to conduct 
a comprehensive review of the benefits and risks of 
Table 2. Suggested dosing of combined inhaled corticosteroids and long-acting beta2-agonists (LABAs) for asthma therapy 
in adults and adolescents ($12 years).
combination  
inhaler
Inhaler  
type
Dose Maximum # of daily  
inhalations  
(regardless of dose)Low Medium High
Budesonide/ 
formoterol  
(Symbicort®)
MDI 80 mcg/4.5 mcg  
(2 inh twice daily)
160 mcg/4.5 mcg 
(2 inh twice daily)
4 inh
Fluticasone/ 
salmeterol  
(Advair®) diskus
DPI 100 mcg/50 mcg  
(one inh twice daily)
250 mcg/50 mcg  
(one inh twice daily)
500 mcg/50 mcg  
(one inh twice daily)
2 inh
Fluticasone/ 
salmeterol  
(Advair®) HFA
HFA 45 mcg/21 mcg  
(2 inh twice daily)
115 mcg/21 mcg  
(2 inh twice daily)
230 mcg/21 mcg  
(2 inh twice daily)
4 inh
Mometasone/ 
formoterol  
(Dulera®)
MDI 100 mcg/5 mcg  
(2 inh twice daily)
200 mcg/5 mcg  
(2 inh twice daily)
4 inh
Abbreviations: inh, inhalation; DPI, dry powder inhaler; HFA, hydrofluoroalkane inhaler; MDI, metered dose inhaler.
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LABAs for the treatment of asthma, which resulted 
in a black box warning that contraindicates LABA 
monotherapy for the treatment of asthma.17 The FDA 
also recommended against LABA use in patients 
whose asthma is well-controlled with low-dose or 
medium-dose ICS alone. In addition, adjunctive 
LABA therapy use should be discontinued, if possible, 
once asthma control is achieved and maintained by 
an asthma controller medication, such as ICS. If 
LABA therapy is utilized, it should be provided as 
a combination inhaler with ICS, never as a separate 
LABA inhaler, in order to minimize the potential 
of overuse. More recently, in April of 2011, the 
FDA updated their recommendation stating that five 
prospective clinical trials will be conducted among 
all age groups to determine whether LABAs, when 
used concurrently with ICS, are safe for the treatment 
of asthma.20 These studies are expected to conclude 
in 2017 and hopefully will provide definitive data 
regarding the safety of LABAs. In the interim, it has 
been suggested that LABA use be restricted to patients 
in whom other adjunctive controller medications, such 
as leukotriene modifiers, do not provide adequate 
asthma control.19
Leukotriene modifiers
Leukotriene modifiers are another class of adjunctive 
controller medication that can be combined with ICS 
for the management of moderate persistent asthma. 
Cysteinyl leukotrienes (leukotriene C
4
, D
4
 and E
4
) are 
pro-inflammatory lipid mediators that are released by 
mast cells, eosinophils and basophils to induce airway 
smooth muscle contraction, tissue edema, eosino-
phil migration and increased airway secretions.3,4,21 
The pathway that generates cysteinyl leukotrienes 
requires the conversion of the precursor fatty acid, 
arachidonic acid, to leukotriene A
4
 by  5-lipoxygenase 
(5-LO), which is then converted to leukotriene C
4
 
or  leukotriene B
4
.21 Leukotriene C
4
 can then be 
metabolized further to generate leukotriene D
4
 and 
leukotriene E
4
, which play important roles in allergen-
mediated airway inflammation. Leukotriene modifiers 
either antagonize the ability of cysteinyl leukotrienes 
to interact with the cysteinyl leukotriene receptor, 
CystLT
1
, or inhibit the enzymatic activity of 5-LO.
Two leukotriene receptor antagonists (LTRA) 
are in clinical use in the United States, montelukast 
( Singulair®) and zafirlukast (Accolate®) (Table 3). 
Both are administered in pill form. Montelukast is 
more commonly utilized for asthma treatment based 
upon its once daily dosing that does not need to be 
coordinated with meals.22 In contrast, zafirlukast 
requires twice daily dosing. Since the bioavailability 
of zafirlukast is decreased 40% by food, it should be 
taken either 1 hour before or 2 hours after meals.23 
Montelukast has a half-life of up to 5.5 hours, a dura-
tion of action that exceeds 24 hours, and undergoes 
hepatic metabolism by CYP3A4 and 2C9.24  Zafirlukast 
has a half life of ten hours, is highly protein bound 
to albumin, and undergoes hepatic metabolism by 
CYP2C9.23 LTRAs are typically well- tolerated with 
few associated side-effects that occur in less than 2% 
of recipients, such as angioedema, anaphylaxis, dizzi-
ness, gastrointestinal symptoms and transaminitis.4,22 
Post-marketing case reports to the FDA have sug-
gested an association between all leukotriene modi-
fying agents, but primarily montelukast, with suicide 
and neuropsychiatric events ( suicidal behavior, 
depression, insomnia) that resulted in the issuance of 
a safety alert.25 Subsequent reviews of this associa-
tion, which were requested by the FDA, did not find 
an increase in suicidal ideation.22,26 Based upon this 
possible association, it is recommended that caution 
be utilized when administering  leukotriene modifiers 
to patients with suicidal ideation or psychiatric symp-
toms. Finally, zafirlukast and montelukast have been 
Table 3. Oral leukotriene modifier medications.23,24,29
Generic name Trade name Medication type Dosage Frequency Modify for meals
Montelukast Singulair® LTRA 10 mg Once daily No
Zafirlukast Accolate® LTRA 20 mg Twice daily 1 hr before or 2 hrs after meals
Zileuton Zyflo CR® 5-LO 1200 mg Twice daily within 1 hr after morning  
and evening meals
Zileuton Zyflo® 5-LO 600 mg Four times/day No
Abbreviations: 5-LO, 5-lipoxygenase inhibitor; LTRA, leukotriene receptor antagonist.
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associated with the development of  Churg-Strauss 
syndrome (CSS), an eosinophilic vasculitis and 
granulomatosis that can be associated with severe 
asthma.4,27 Although this association was initially 
thought to reflect an unmasking of underlying CSS 
caused by a reduction in oral corticosteroid therapy, a 
recent review of 181 reported cases of drug-induced 
CSS in the FDA Adverse Event Reporting System 
showed that a LTRA was a suspect medication in 90% 
of cases.28 Furthermore, in the majority of cases, CSS 
could not be explained by either corticosteroid with-
drawal or pre-existing CSS. This suggests that LTRA 
therapy might have a direct role in the pathogenesis 
of CSS.
Zileuton is the only 5-lipoxygenase inhibitor cur-
rently approved for treatment of asthma in the United 
States. It is orally administered and requires dosing 
either 4 times daily for the regular formulation or 
twice daily for the controlled release formulation.22 
Zileuton undergoes gastrointestinal and hepatic 
metabolism via CYP1A2, 2C9, and 3A4.29 The 
safety profile of zileuton is similar to LTRAs with the 
exception of transaminitis, which occurs in 4.4% of 
cases, but is typically not associated with jaundice or 
liver failure.30 Therefore, liver function tests should 
be monitored monthly during the first three months 
of treatment and every 2 to 3 months during the first 
year, as well as periodically in subsequent years.22,30 
Other side effects that have been associated with zile-
uton include headache, gastrointestinal symptoms, 
myalgias, leukopenias, sleep disorders and behavior 
changes.22
The EPR-3 recommends the addition of a LTRA 
to low-dose ICS as Step 3 therapy or medium-dose 
ICS as Step 4 therapy (Fig. 2). Results of random-
ized clinical trials have suggested that LABAs are 
superior to LTRAs as add-on therapy based upon 
their ability to decrease symptoms and exacerbations 
when asthma symptoms are not adequately controlled 
with ICS alone.22,31,32 Recently, a community-based, 
multicenter trial compared the addition of a LTRA or 
LABA when patients were inadequately controlled 
by ICS.32 This “real world” study followed patients 
for 2 years and showed that LTRAs were equivalent 
to LABAs as add-on therapy for a diverse group of 
primary care patients who were not adequately con-
trolled with ICS alone, using the miniAQLQ as the 
primary outcome measure. Furthermore, treatment 
with a LTRA was equivalent to an ICS as first-line 
controller medication. When these results are consid-
ered in the context of the uncertainty regarding the 
safety of LABAs for the treatment of asthma, clini-
cians may favor the addition of a LTRA, rather than 
a LABA, as initial step-up therapy when patients are 
persistently symptomatic on ICS alone.33 The ease of 
daily oral administration of LTRAs (montelukast), as 
well as their favorable safety profile and effective-
ness for treatment of allergic rhinitis are additional 
reasons for clinicians to consider initial step-up 
therapy with LTRA in patients who are persistently 
symptomatic despite ICS. Furthermore, patients with 
 aspirin-sensitive asthma, exercise-induced asthma and 
those with asthma exacerbations secondary to viral 
upper respiratory tract infections may be more likely 
to benefit from leukotriene modifier therapies.22
Theophylline
The xanthine derivative, theophylline, is an orally 
administered, non-selective phosphodiesterase inhibi-
tor that mediates airway smooth muscle relaxation by 
increasing cAMP levels, and may also possess mild 
anti-inflammatory activities.3,34 EPR-3 recommends 
sustained release theophylline as an alternative , but 
not preferred, controller medication that can be added 
when asthma symptoms are not adequately controlled 
by ICS.3 Consistent with this recommendation, addi-
tion of theophylline to low-dose ICS has been shown 
to be as effective as increasing the dose of ICS for 
improving control of asthma symptoms.35,36 However, 
comparison of step-up therapy with theophylline to 
LABAs has shown that LABAs (ie, salmeterol) are 
superior in improving morning and evening peak 
expiratory flow rates, as well as in reducing the use of 
rescue medication, while no differences were noted in 
improving FEV
1
.36,37 Step-up therapy with the addition 
of theophylline, however, is associated with a higher 
incidence of central nervous system and gastrointes-
tinal side effects. Few studies have directly compared 
step-up therapy with theophylline to LTRAs.36,38,39
Although theophylline has been used to treat 
asthma for over 70 years, its role has been limited 
by its narrow therapeutic range, variable inter-patient 
pharmacokinetics, multiple drug interactions and 
common side effects.34,36 Theophylline has a half-life 
of 8.7 hours in non-smoking adults that is dependent 
upon age, cardiac and liver function, lung disease 
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and smoking history. Theophylline undergoes hepatic 
metabolism via CYP1A2, CYP2E1, and CYP3A4 to 
produce active metabolites, including caffeine and 
3-methylxanthine.40 Monitoring of serum theophyl-
line concentrations is required to ensure that toxic 
levels are avoided by maintaining serum levels in the 
range of 10 to 20 mcg/mL.41 Theophylline-associated 
toxicities are more significant than other commonly 
used medications for moderate asthma and include 
gastrointestinal (vomiting, abdominal pain), cardiac 
(ventricular arrhythmias), neurologic (seizures), mus-
culoskeletal (tremors), and metabolic (hypokalemia, 
hyperglycemia) toxicities. Another limitation regard-
ing the use of theophylline is the presence of mul-
tiple drug interactions with common medications 
that can result in theophylline-associated toxicities 
due to increased serum drug levels (Table 4). Taken 
together, theophylline is not utilized as a preferred 
adjunctive step-up controller medication to ICS when 
asthma is poorly controlled.3 Instead, step-up therapy 
with theophylline is typically reserved for patients in 
whom inhaled medications can not be adequately uti-
lized and other adjunctive step-up medications have 
not been effective.
Allergen immunotherapy
The EPR-3 recommends that subcutaneous allergen 
immunotherapy (AIT) also be considered for patients 
who have persistent asthma if there exists a clear 
 relationship between asthma symptoms and exposure 
to the offending allergen.3 AIT is typically utilized 
when patients have symptoms during at least a major 
portion of the year and are persistently symptomatic 
despite use of multiple controller medications. There is 
evidence that immunotherapy needs to be administered 
for prolonged periods, typically three to five years, to 
be effective.3,42,43 A recent update of a Cochrane review 
of 88 trials of injection allergen immunotherapy for 
asthma concluded that AIT reduces asthma symptoms 
and the use of asthma medications, as well as improves 
allergen-specific bronchial hyperreactivity, but does not 
have a consistent effect on lung function.43 Systemic 
reactions to AIT were frequent, occurring in one out of 
nine patients. Since subcutaneous AIT can be associ-
ated with severe and sometimes fatal allergic reactions, 
especially severe bronchoconstriction, therapy should 
only be administered in a health care provider’s office.3 
Similarly, a Cochrane style meta-analysis of 25 trials 
of sublingual immunotherapy for asthma concluded 
that there was a significant reduction in asthma sever-
ity, but not asthma symptoms, which suggests that the 
magnitude of the effect is not very large.44 No severe 
reactions were noted in these studies, which repre-
sents an advantage of sublingual over subcutaneous 
immunotherapy. Potential mechanisms that mediate 
the effectiveness of AIT include induction of tolerance 
by allergen-specific regulatory T cells with resultant 
increases in allergen-specific IgG4 and decreases in 
Table 4. examples of common medications that can modify serum theophylline levels.40
Medication class Increase serum theophylline levels Decrease serum theophylline levels
Asthma/allergy Zafirlukast
Zileuton
Antibiotics Ciprofloxacin, Norfloxacin, Ofloxacin Protease inhibitors
Isoniazid Rifampin
Macrolides (except azithromycin, telithromycin)
Thiabendazole
Anti-metabolites Allopurinol
Methotrexate
Cardiovascular Amiodarone
Mexiletene
Propafenone
Neurologic Barbiturates
Carbamazepine
Phenytoin
Miscellaneous Cimetidine
Disulfiram
estrogens
Pentoxyfylline
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Th2 cells, IgE and eosinophilia.45,46 Sublingual AIT 
may also decrease allergic responses via stimulating 
oral Langerhans cells.46 New forms of immunotherapy 
are currently under development which may advance 
further the role of AIT for the treatment of allergic 
disease.45
putting it all Together: Management  
of Moderate Asthma
The EPR-3 recommends that patients with moder-
ate persistent asthma initiate therapy at Step 3, which 
includes an ICS alone or in combination with an 
adjunctive controller medication.3 This recommen-
dation is based upon the potent anti-inflammatory 
properties of ICS that attenuate the airway inflamma-
tion that underlies the pathogenesis of asthma. Thus, 
therapy for moderate persistent asthma may be initi-
ated with either a medium dose ICS or a low-dose 
ICS in combination with either a LABA, LTRA or 
theophylline. Although combination therapy with 
an ICS plus a LABA had frequently been utilized as 
the medication of choice for this patient population, 
safety concerns regarding LABAs have supported the 
concept that LABAs be utilized with caution until 
definitive data are available regarding their effect on 
asthma-associated mortality.19 Therefore, clinicians 
and patients may opt to initiate therapy with either a 
medium dose ICS alone or a low-dose ICS in com-
bination with a LTRA instead of an ICS in combina-
tion with a LABA. Furthermore, monotherapy with 
a LABA should never be utilized as a treatment for 
asthma. The addition of theophylline to a low-dose 
ICS is a non-preferred option due to the potential for 
toxicity and the need for monitoring of serum  levels. 
Similarly, 5-LO inhibition with zileuton is a less desir-
able option due to more limited efficacy data and the 
need to monitor liver function tests.3
Patient preference also needs to be considered 
when devising an asthma treatment plan, as a 
significant proportion of asthmatics with sub-optimally 
controlled asthma are non-adherent with prescribed 
treatments.47 In particular, non-adherence rates with 
controller medications range from 30% to 70%, while 
approximately 20% may not acquire any controller 
medication at all.48 Inclusion of patient preferences in 
the decision making process regarding asthma treatment 
may improve adherence to treatment. Factors that may 
improve compliance include use of a combination 
inhaler as opposed to two single inhalers, as well as 
the use of oral agents as compared with inhalers, as 
it is easier to swallow a pill than to properly use an 
inhaler.32,49 Furthermore, improper inhaler technique 
is common and is associated with poor disease control 
and increased risk of hospitalization or emergency 
department visits, especially in patients who are older, 
have less education and have not received proper 
instruction by health care providers.50,51 Compliance 
may be improved by education about the disease and 
proper inhaler technique.50,52
Frequency of administration may also impact 
compliance, as it is easier to adhere to a once daily 
medication than one that requires repeated dosing.53 
Similarly, compliance may be more difficult with 
medications that require periodic monitoring, such as 
zileuton or theophylline. Therefore, asthma manage-
ment therapies need to be tailored to the preference 
of individual patients to increase adherence with pre-
scribed treatments.
After therapy has been initiated, patients should 
be monitored at two to six week intervals to ensure 
that symptom control has been achieved.3 Patients are 
not well-controlled if they have asthma symptoms 
more frequently than twice a week, utilize a rescue 
short-acting beta
2
-agonist inhaler more than twice a 
week, have nocturnal awakenings more than twice 
per month, FEV
1
 or a peak flow less than 80% of pre-
dicted, or have evidence of poor control on a validated 
asthma questionnaire (Fig. 3). If asthma symptoms are 
not well-controlled, then therapy should be “stepped 
up” by either increasing the ICS dose from low 
dose to medium-dose or by the addition of a LTRA, 
LABA or theophylline to medium dose ICS (Fig. 2). 
 Allergen immunotherapy may also be considered as 
an adjunct therapy in individuals with atopic asthma 
who are chronically exposed to the offending allergen. 
 Additionally, the patient’s inhaler technique should be 
reviewed, as well as their compliance with therapy. 
Furthermore, an investigation to determine whether 
environmental factors, such as allergens, pollutants or 
irritants, or co-morbid conditions, such as gastrointes-
tinal reflux or rhinosinusitis, are preventing adequate 
control of asthma symptoms. If these measures fail 
to improve asthma control, then therapy should be 
“stepped up” further to Steps 5 or 6 for severe asthma, 
as needed, which includes the options of anti-IgE 
therapy (omalizumab) and oral corticosteroids.
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Once asthma symptoms are well-controlled 
for a period of 3 months, then consideration can 
be given to “stepping down” therapy, which is an 
equally important goal of asthma therapy in order 
to minimize side effects that can be associated with 
the long-term use of asthma controller medications. 
For example, although ICS have few side effects, 
systemic absorption occurs and can be associated 
with a reduction in bone growth in children.8,33 
 Furthermore, high dose ICS can be associated with 
an increased risk of cataracts and fractures in high-
risk adults.8 Consistent with this approach, a recent 
community-based study of supervised step-down 
therapy confirmed that a significant reduction in 
ICS dose could be achieved without deterioration of 
airway inflammation or function.54 Given the recent 
safety concerns, consideration may be given to with-
drawal of LABAs. However, stepping down to ICS 
monotherapy may be associated with poorer asthma 
control as compared to a reduction in dose of ICS 
with continuation of the LABA.55–57  Consideration 
might also be given to “stepping down” from other 
medications with potential side effects, such as theo-
phylline or zileuton.
conclusions
Moderate asthma is a common, but challeng-
ing, disease that is frequently managed by general 
practitioners, as well as specialists. Patients with 
moderate asthma can be difficult to manage and 
typically require more than one controller drug, as 
well as therapy for co-morbid conditions, such as 
environmental allergies, gastroesophageal reflux or 
 rhinosinusitis. Involvement of health care providers 
in the individualization of medication regimens, as 
well as in patient education, are crucial to optimizing 
compliance with therapy and disease control. Health 
care providers also need to be continually aware of 
emerging data regarding the utilization and safety of 
controller medications that can significantly impact 
disease management. Lastly, the development of new 
asthma treatments, perhaps based upon personalized 
medicine, has the potential to revolutionize the future 
therapy of moderate asthma.
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